New PET tracer could spot hidden heart nerve damage in ICD patients

NCT ID NCT06965621

Recruiting now Diagnosis Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase 2 study tests a new radioactive imaging agent, 18F-mFBG, to measure nerve damage in the hearts of 20 people with stable heart failure and implantable defibrillators (ICDs). The goal is to see if the agent can reveal differences in nerve function between those who have had a shock from their ICD and those who have not. The study will also compare the new agent to existing imaging methods and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-metaFluorobenzylguanidine (18F-mFBG)
What this could lead to: If successful, this imaging method could help doctors better identify which heart failure patients are at risk of dangerous heart rhythms, potentially improving ICD therapy decisions.
What could go wrong: This is a small, early-phase study (20 people) focused on imaging, not treatment. The new agent may not prove better than existing methods, and safety data are still being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy dilated cardiomyopathy heart failure impulse control disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE ICD PATIENTS ISCHEMIC CARDIOMYOPATHY

Contacts and locations

Locations

UT Health Houston
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.